Design Therapeutics Inc
NASDAQ:DSGN
Design Therapeutics Inc
NASDAQ:DSGN
Price:
3.78 USD
0.53%
Market Closed
Updated:
Apr 27, 2024
Design Therapeutics Inc
Cash from Financing Activities
|
Design Therapeutics Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Design Therapeutics Inc
NASDAQ:DSGN
|
Cash from Financing Activities
$724k
|
CAGR 3-Years
-75%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
16%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Design Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
724k
USD
724k
USD
Based on the financial report for Dec 31, 2023, Design Therapeutics Inc's Cash from Financing Activities amounts to 724k USD.
What is Design Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-75%
-75%
Over the last year, the Cash from Financing Activities growth was 202%. The average annual Cash from Financing Activities growth rates for Design Therapeutics Inc have been -75% over the past three years .
You don't have any saved screeners yet
